Sorry, you need to enable JavaScript to visit this website.


Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B.

Download the Trumenba Brochure to find out more about how Trumenba can help to protect adolescents and young adults against IMD caused by Men B.

Trumenba eModule

This eModule aims to help those delivering a Men B vaccine service, This module is accompanied by a short question based knowledge check to help evaluate what you know. In addition, there will be disease background modules available for IMD under the Nimenrix eModules to assist your learning. Access the eModule here.

See section Risk & Reporting for how to report adverse reactions.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the summary of product characteristics for how to report adverse reactions.